Abstract
Preclinical laboratory science has revealed multiple new targets for breast cancer therapy. Clinical trials targeting key signaling pathways are underway and a number of new drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal antibodies and tyrosine kinase inhibitors were among the first to be approved, but new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have also shown promise. This review will evaluate potential new targets and specifically targets in hormone receptor positive and triple negative breast cancer.
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin, phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Current Cancer Therapy Reviews
Title:New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways
Volume: 11 Issue: 4
Author(s): John P. Schwerkoske and Douglas Yee
Affiliation:
Keywords: Breast cancer, estrogen receptor, growth factor receptors, mammalian target of rapamycin, phosphatidylinositol 3-kinase, tyrosine kinase inhibitors.
Abstract: Preclinical laboratory science has revealed multiple new targets for breast cancer therapy. Clinical trials targeting key signaling pathways are underway and a number of new drugs have been approved for treatment. Targeting of growth factor receptors by monoclonal antibodies and tyrosine kinase inhibitors were among the first to be approved, but new small molecules inhibiting the phosphatidylinositol 3-kinase signaling pathway have also shown promise. This review will evaluate potential new targets and specifically targets in hormone receptor positive and triple negative breast cancer.
Export Options
About this article
Cite this article as:
P. Schwerkoske John and Yee Douglas, New Ways to Improve Breast Cancer Therapy Targeting Specific Molecular Pathways, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151215220005
DOI https://dx.doi.org/10.2174/1573394712666151215220005 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Application of Remote Ischemic Preconditioning in Patients Undergoing Chemotherapy with Anthracyclines
Current Enzyme Inhibition <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry Αlpha-2 Adrenergic and Opioids Receptors Participation in Mice Gastroprotection of Abelmoschus esculentus Lectin
Current Pharmaceutical Design Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments
Recent Patents on Anti-Cancer Drug Discovery Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Patent Selections
Recent Patents on Biomarkers Thalidomide Controls Adipose Tissue Inflammation Associated with High- Fat Diet-Induced Obesity in Mice
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Nanosponge Carriers- An Archetype Swing in Cancer Therapy: A Comprehensive Review
Current Drug Targets Specialisation of the Tropomyosin Composition of Actin Filaments Provides New Potential Targets for Chemotherapy
Current Cancer Drug Targets α(N)-Heterocyclic Thiosemicarbazones: Iron Chelators that are Promising for Revival of Gallium in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Preface - Special Issue “Mini-Reviews in Medicinal Chemistry” Proceedings of the Twentieth Anniversary of the Faculty of Pharmacy of the University of Calabria
Mini-Reviews in Medicinal Chemistry The Role of the Gastrointestinal Microbiota in Colorectal Cancer
Current Pharmaceutical Design Drug release from ordered mesoporous silicas
Current Pharmaceutical Design Synergistic Effect of Novel EGFR Inhibitor AZD8931 and p38α siRNA in Lung Adenocarcinoma Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Anti-inflammatory Phytochemicals for Chemoprevention of Colon Cancer
Current Cancer Drug Targets Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Identifying Breast Cancer-induced Gene Perturbations and its Application in Guiding Drug Repurposing
Current Bioinformatics Towards Human on a Chip: Recent Progress and Future Perspective
Micro and Nanosystems